The purpose of this study is to determine if the addition of antiplatelet therapy (i.e.
aspirin) to low-molecular-weight-heparin (i.e. enoxaparin) will decrease the incidence of
venous thromboembolism (VTE) in high-risk critically injured patients. The investigators
further aim to determine the safety and efficacy of dual thromboprophylaxis with aspirin and
enoxaparin for decreasing the incidence of VTE after trauma.